44 results about "Lung cancer susceptibility" patented technology

The present invention relates to certain immunoreactive polypeptides, methods for aiding in the diagnosis of lung cancer in a subject and kits for performing said methods.

The invention relates to the field of genetic engineering, and provides a method and a corresponding kit for detecting a lung cancer susceptibility gene. The method for detecting the lung cancer susceptibility gene comprises the following steps of: A, using a specificity primer of the lung cancer susceptibility gene to amplify a plurality of target areas in a sample to be detected, and establishing a sequencing library based on amplified products; B, subjecting the sequencing library to monomolecular amplification to obtain a plurality of monomolecular amplification products corresponding to the plurality of target areas; and C, subjecting the plurality of monomolecular amplification products to high-throughput gene sequencing at the same time so as to obtain sequence information of the plurality of target areas. The method and the corresponding kit are used for sequencing the plurality of areas of the lung cancer susceptibility gene at the same time by using a high-throughput sequencing technology; the sequence information including variation of known mutations and unknown mutations in the areas can be obtained accurately; the kit has high detection sensitivity, and can be used for further detecting mainly samples at the same time.

The invention discloses a reagent kit for detecting lung cancer susceptibility, comprising a common component for fluorescence quantitative PCR detection, and a specific primer pair and a specific fluorescent probe which detect the NO. rs1136410 SNP site of PARP1 gene, the NO. rs1048943 SNP site of CYP1A1 gene, the NO. rs25487 SNP site of XRCC1 gene, the NO. rs13181 SNP site of ERCC2 gene and the NO. rs1799793 SNP site of ERCC2 gene at the same time. The reagent kit can predict the lung cancer susceptibility of individual through detecting the SNPs site genotype of PARP1 gene, CYP1A1 gene, XRCC1 gene and ERCC2 gene of individual at the same time.

The invention discloses a kit for detecting lung cancer susceptibility by MAP2K4 gene and application thereof. The kit contains the following substances: specific primer pair and specific fluorescent probe pair which are used for detecting SNP site rs3826392 on MAP2K4 gene, Taq DNA polymerase, dNTP mixed solution, MgCl2 solution, fluorescent quantitative PCR reaction buffer solution and deionized water as well as specific primer; wherein the sequence of specific primer pair used for detecting SNP site rs3826392 on MAP2K gene contains a sense primer sequence and an antisense primer sequence; the specific fluorescent probe pair used for detecting SNP site rs3826392 on MAP2K4 contains a wild type probe sequence and a mutant type probe sequence; and the specific primer can specifically amplify DNA primer pair and DNA probe pair which direct at the SNP site rs3826392 on MAP2K4 gene. The invention detects lung cancer susceptibility by detecting SNP site rs3826392 on MAP2K4 gene and can be widely applied to medical research.

The invention belongs to the field of gene detection and particularly relates to a nucleic-acid mass spectrometry detection method for early screening of drive genes and susceptible genes of lung cancer. The nucleic-acid mass spectrometry detection method has the characteristics that by consideration of the difference of the lung-cancer gene spectra of the Asian populations and European-American populations, 29 lung-cancer hotspot mutations and 20 mononucleotide polymorphic sites significantly-related to suffering risk of the Asian populations are selected and combined, drive genes and susceptible genes of detection are advanced, multiple sites related to lung-cancer susceptibility and targeted-therapy drug resistance are introduced and are independent mutually without unbalanced linkage, therefore, site selection has representativeness, independence and risk-value accumulation, and can be used for evaluating the risk of individuals suffering from the lung cancer; and the detection technology is obvious in price advantage, higher in sensitivity at the aspect of lung-cancer early screening detection and larger in flux, can realize detection of multiple genes of single small samples to meet the maximum use of the small samples, and can realize translational research in clinical application.

The invention discloses an SNP (Single Nucleotide Polymorphism) marker for detecting the susceptibility to lung cancer. The SNP marker comprises 36 SNP loci. The invention further discloses a PCR (Polymerase Chain Reaction) amplification primer and a single-base extension primer of the SNP marker as well as a kit of the SNP marker. An important basis is provided for prevalence risk assessment and diagnostic reference of the lung cancer, so that early diagnosis of the lung cancer is realized.

The invention relates to a disposable multicolor fluorescence combined augmentation reagent kit for 11 SNP gene loci which are related to lung cancer / munity for extracorporeal use, comprising separately packed primer mixture, DNA polymerase, buffer solution, quality control DNA specimen and allele parting normal mixture. Wherein, the primer mixture consists of 11 sharing primers marked by fluorescence and 22 length specificity primers specific to different alleles, the invention particularly consists of 2.0ml of primer mixture (therein gene locus has different primer consistency, 30nM-240nM), 1000u of DNA polymerase, 2.0ml of buffer solution, 1ml of the total amount of allele parting normal mixture, and 0.1ml (10ng / ul) of quality control DNA. Under the condition of best primer mixture ratio, the invention can rapidly and accurately obtain the genotypes of the 11 SNP points related to the lung cancer munity.

The invention provides a method for detection of lung cancer, or predisposition to lung cancer, in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of lung cancer, or predisposition to lung cancer. The method can be adapted for quantitatively monitoring the efficacy of treatment of lung cancer in a subject. Markers of DNA damage include single- and / or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitrotyrosine oxidative activity (protein nitrosylation in leukocytes). This unexpected discovery of markers of systemic genotoxicity that can be tested using circulating leukocytes enables detection of lung cancer, or predisposition to lung cancer, with a relatively simple and minimally invasive assay using peripheral blood.

The invention discloses a primer set for detecting the genotype of an rs2066853 site and a detection kit and application thereof. The primer set comprises a pair of specific primers, a wild-type fluorescent probe and a mutant fluorescent probe, and the sequences thereof are sequentially shown as SEQ ID NOs: 1-4; a detection method comprises the following specific steps: S1, extracting DNA from a sample to be detected; S2, with the DNA in the step S1 as a template, performing fluorescent quantitative PCR detection by using the primers to determine the genotype of the rs2066853 site; through the genotype of the site, lung cancer susceptibility assessment can be performed, and if the genotype of the rs2066853 site is A, the sample is susceptible to lung cancer. The rs2066853 site detecting primers designed by the invention are strong in specificity and high in amplification efficiency; the adopted detection method is simple, convenient and efficient; automatic result judgment is achieved; the primer set has a relatively good application prospect in disease prevention and detection.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 161 in CYPIAI gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention discloses a primer group for detecting a p.Pro189Ala site genotype as well as a detection kit and application thereof. The primer group comprises a pair of specific primers and two wild and mutant fluorescent probes, and a sequence thereof is successively shown as SEQ ID NO. 1 to SEQ ID NO. 4. The detection method specifically comprises the following steps: S1, extracting DNA of a sample to be detected; S2, performing fluorescent quantitative PCR detection by using the primer with the DNA of step S1 as a template, and determining a genotype of a p.Pro189Ala site; and evaluating the lung cancer susceptibility by virtue of the genotype of the site, wherein if an amino acid for coding the p.Pro189Ala site is Ala, the sample is susceptible to the lung cancer. The p.Pro189Ala site detection primer designed by the present invention is high in specificity and high in amplification efficiency; and the adopted detection method is simple and efficient, the automation of a determination result is realized, and the application prospect in the disease prevention and detection is relatively great.

The invention provides a kit for detecting lung cancer susceptibility genes. The kit comprises a primer aiming at a single nucleotide polymorphism site rs4488809 (T-C) on a TP63 gene, a primer aiming at a single nucleotide polymorphism site rs36600 (T-C) on an MTMR3 gene, and a primer aiming at a single nucleotide polymorphism site rs2395185 (G-T) on an HLA gene.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1799793 and the SNP locus of No. rs13181 on an ERCC2 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer by detecting the gene carrying type of the two different SNPs loci on the ERCC2 gene of the individual synchronously.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting 161st SNP site in SEQ ID NO:1 of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing the type of carried gene at SNP site of individual PARP1 gene.

The present invention relates to a lung cancer susceptibility gene noninvasive detection kit which includes a mixture of a plurality of lung cancer susceptibility gene specific amplification primers, a sequencing primer and a PCR amplification reagent premix. The detection kit can simultaneously detect multiple areas of the lung cancer susceptibility gene, sequence information in the areas can be exactly obtained, according to the comprehensive information of each locus mutation by combination with susceptibility risk degree assessment method, lung cancer risk can be calculated, detection sensitivity is high, and further large number of samples can be simultaneously detected.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs1048943 SNP locus on gene CYP1A1 and No. rs13181 SNP locus on gene ERCC2, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene CYP1A1 and ERCC2 to predict susceptibility of the individual to lung cancer.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs25478 SNP locus on gene XRCC1 and No. rs1048943 SNP locus on gene CYP1A1, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene XRCC1 and CYP1A1 to predict susceptibility of the individual to lung cancer.

The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1136410 SNP locus on an PARP1 gene, an rs25487 SNP locus on a XRCC1 gene and an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the PARP1 gene, the XRCC1 gene and the ERCC2 gene of the individual.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1799793 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and ERCC2 gene.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention relates to an SNP marker related to auxiliary diagnosis of Chinese non-small cell lung cancer and application thereof. The marker is rs2046210. According to the invention, a technical method for screening non-small cell lung cancer high-risk groups is provided at molecular biology and gene diagnosis levels. The method based on early research shows that the BPA exposure level and thers2046210 site jointly influence the non-small cell lung cancer susceptibility of the Chinese population. Genotyping is carried out by developing a high-sensitivity BPA level measurement platform andcarrying out ingenious primer and probe design for an rs2046210 site and thus the high-risk group of the non-small cell lung cancer can be identified; and the diagnosis of the non-small cell lung cancer patients are helped. The method is ingenious, simple and feasible, is accurate and reliable in result and can be popularized in hospitals at all levels; the assistance is provided for evaluation ofrisk of the non-small cell lung cancer; and the clinical screening and early intervention of the non-small cell lung cancer for the group of people are facilitated.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1136410 SNP site of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and PARP1 gene.

The present invention discloses a kit used for inspection of susceptibility of lung cancer. The kit comprises not only a specific primer couple and a specific fluorescent probe, which are capable of inspecting at the same time the site SNP of No. rs25487 of gene XRCC1, both the site SNP of No. rs13181 and the site SNP of No. rs1799793 of gene ERCC2, but also a standard component used for fluorescent quantitative PCR. The kit provided by the present invention predicts the individual susceptibility to lung cancer through mutual analysis on the gene type on the site of SNPs of both the gene XRCC1 and gene ERCC2.

The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1048943 SNP locus on a CYPIA1 gene, an rs1136410 SNP locus on an PARP1gene, an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the CYPIA1 gene, the PARP1 gene and the ERCC2 gene of the individual.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs1799793 on an ERCC2 gene and the SNP locus of No. rs25487 on a XRCC1 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs13181 and the SNP locus of No. rs1799793 on an ERCC2 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs1799793 SNP locus on gene ERCC2 and No. rs1136410 SNP locus on gene PARP1, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene ERCC2 and PARP1 to predict susceptibility of the individual to lung cancer.

The invention discloses a primer group for detecting a p.Pro189Ala site genotype as well as a detection kit and application thereof. The primer group comprises a pair of specific primers and two wild and mutant fluorescent probes, and a sequence thereof is successively shown as SEQ ID NO. 1 to SEQ ID NO. 4. The detection method specifically comprises the following steps: S1, extracting DNA of a sample to be detected; S2, performing fluorescent quantitative PCR detection by using the primer with the DNA of step S1 as a template, and determining a genotype of a p.Pro189Ala site; and evaluating the lung cancer susceptibility by virtue of the genotype of the site, wherein if an amino acid for coding the p.Pro189Ala site is Ala, the sample is susceptible to the lung cancer. The p.Pro189Ala site detection primer designed by the present invention is high in specificity and high in amplification efficiency; and the adopted detection method is simple and efficient, the automation of a determination result is realized, and the application prospect in the disease prevention and detection is relatively great.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs1048943 SNP site of CYP1A1 gene and no. rs1136410 SNP site of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual CYP1A1 and PARP1 gene.